# Kearny Venture Partners

> Kearny Venture Partners is a VC fund backing Health Care and Biotechnology. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 14
- Last investment: Aug 2024
- Lead investor: 7%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kearny-venture-partners/about/
- Website: http://www.kearnyvp.com

Kearny Venture Partners is a VC fund in San Francisco focused on Health Care and Biotechnology. With over $330 million in capital under management, Kearny Venture Partners is a venture capital firm exclusively focused on healthcare products. We believe that the opportunity for entrepreneurs to devise innovative solutions in healthcare has never been greater. Significant unmet needs in healthcare continue to persist, representing largepotential market opportunities for safe and effective products. As the molecular basis of disease is increasingly unraveled, new opportunities for intervention emerge. Novel therapies can and will displace incumbent products.

## Contacts

5 contacts available for Kearny Venture Partners. Shizune tracks 5 team members at Kearny Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kearny-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 43% |
| Biotechnology | 6 | 43% |
| Therapeutics | 3 | 21% |
| Medical Device | 3 | 21% |
| Manufacturing | 1 | 7% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 29% |
| Series C | 4 | 29% |
| Series A | 2 | 14% |
| Series D | 1 | 7% |
| Series E | 1 | 7% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 43% |
| Canada | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew Jensen | CFO | 0 | https://shizune.co/investors/profile/andrew-jensen-2 |
| Anupam Dalal | Managing Director | 0 | https://shizune.co/investors/profile/anupam-dalal |
| Caley Castelein | Partner | 0 | https://shizune.co/investors/profile/caley-castelein |
| Dick Spalding | Managing Director | 0 | https://shizune.co/investors/profile/dick-spalding |
| Jim Shapiro | Managing Director | 7 | https://shizune.co/investors/profile/jim-shapiro |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Elektrofi | Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience. Elektrofi’s formulation system can effectively process a wide range of therapeutic molecules. Their technology has the capacity to process large, increasingly complex and delicate proteins including monoclonalantibodies, bispecifics and fusion proteins.Founded in 2016, Elektrofi is based in Boston, Massachusetts, United States. | $112.3M | Series C | Aug 22, 2024 |  |
| Cybin | Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $33.1M | Series B | Jul 01, 2020 |  |
| Aerpio Pharmaceuticals | Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States. | $40M |  | Mar 16, 2017 |  |
| TriVascular | TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $40M | Series E | Nov 18, 2013 |  |
| TriVascular | TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $60M | Series D | Jun 04, 2012 |  |
| ViewRay | ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRItechnology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery.The company was incorporated in 2004 and is based in Cleveland, Ohio. | $10M | Debt Financing | Sep 02, 2011 |  |
| ViewRay | ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRItechnology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery.The company was incorporated in 2004 and is based in Cleveland, Ohio. | $20M | Series C | Aug 25, 2010 |  |
| TriVascular | TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $60M | Series C | Aug 12, 2010 |  |
| Baxano | Baxano, Inc. develops minimally invasive tools to restore spine function and preserve healthy tissue. The company offers iO-Flex System, which targets and decompresses bone and soft tissue in the foramen, lateral recess, and central canal for patients with single and multi-level mild, moderate, and severe stenosis. Its products comprise Neuro Checkdevice that allows the surgeon to confirm that the device is against the bone and the nerve is safely out of the way; MicroBlade ShaverTM instrument, which is used to remove the impinging bone and ligament; Guidewire; probes; and distal handles. The company was founded in 2005 and is based in San Jose, California. | $30M | Series C | Jun 23, 2010 |  |
| TriVascular | TRIVASCULAR is committed to developing new medical devices that address unmet clinical needs while providing an excellent working environment for its employees. The company was founded by Michael Chobotov, Ph.D., Robert Whirley, Ph.D., and Joseph Humphrey, Ph.D. TriVascular is located 50 miles north of San Francisco in the heart of the Sonoma WineCountry. TriVascular offers excellent career opportunities, benefits and quality of life to its employees. TRIVASCULAR's first products are next-generation transluminally placed endovascular grafts, often referred to as stent-grafts, for the treatment of aneurysmal disease in the abdominal aorta (AAA) and the thoracic aorta (TAA). Such endovascular procedures can lead to substantially lower mortality, morbidity, and cost compared to open surgical repair. TriVascular has developed a novel device design that achieves a low profile, permitting substantially improved access through the vasculature. | $30M | Series B | Nov 16, 2009 |  |

10 of 14 investments shown.

## Co-investors
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 5 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 5 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 5 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 3 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Kearny Venture Partners invest in?

Kearny Venture Partners invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Series C stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kearny Venture Partners?

Public channels for Kearny Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kearny Venture Partners?

The team at Kearny Venture Partners includes Andrew Jensen (CFO), Anupam Dalal (Managing Director) and Caley Castelein (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co